Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China flag China · Delayed Price · Currency is CNY
45.56
-2.54 (-5.28%)
Aug 21, 2026, 3:00 PM CST

SHA:688513 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
328.01855.43971.4781.23830.971,051
Trading Asset Securities
1,345758452.35741.78516.36453.84
Cash & Short-Term Investments
1,6731,6131,4241,5231,3471,505
Cash Growth
8.58%13.32%-6.52%13.04%-10.45%-7.43%
Accounts Receivable
197.07257.78288.44177.7180.92126.73
Other Receivables
0.520.310.440.661.250.17
Receivables
197.59258.09288.88178.36182.17126.9
Inventory
247.99228.71190.09160.98140.87103.68
Prepaid Expenses
-3.254.224.112.783.2
Other Current Assets
43.9428.6821.7616.4125.9740.76
Total Current Assets
2,1622,1321,9291,8831,7091,779
Property, Plant & Equipment
1,2191,2241,2491,2551,141874.59
Long-Term Investments
76.8271.2180.7181.0846.66-
Goodwill
23.123.1----
Other Intangible Assets
213.97207.0135.634.4634.6133.71
Long-Term Deferred Tax Assets
18.723.6811.58.578.7312.16
Long-Term Deferred Charges
89.4599.1777.5154.9245.3612.35
Other Long-Term Assets
20.917.3416.7329.8932.0963.39
Total Assets
3,8243,7983,4003,3473,0182,775

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
134.16124.98144.35180.94156.86203.92
Accrued Expenses
31.95261.38266.85218.97190.72156.1
Short-Term Debt
115.01110.7174.44180.95105.2920.02
Current Portion of Long-Term Debt
4.44.43.672.93--
Current Income Taxes Payable
33.8615.14.623.341.462.71
Current Unearned Revenue
33.1723.3138.2831.9828.7110.99
Other Current Liabilities
313.1278.8264.1241.9846.3538.72
Total Current Liabilities
665.67618.7596.32661.09529.39432.46
Long-Term Debt
29.3331.5335.9339.6--
Long-Term Unearned Revenue
63.1662.4968.2541.1842.8151.03
Long-Term Deferred Tax Liabilities
44.2646.191.71.460.880.12
Total Liabilities
802.42758.9702.21743.33573.08483.6

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
176.53176.53176.53120.09120.09120.09
Additional Paid-In Capital
1,3951,4041,3881,4441,4441,444
Retained Earnings
1,4631,4191,2081,040880.3727.45
Treasury Stock
-103.45-67.67-76.22-1.59--
Comprehensive Income & Other
1.961.261.020.990.020.07
Total Common Equity
2,9332,9332,6982,6032,4442,292
Minority Interest
88.49106.14----
Shareholders' Equity
3,0223,0392,6982,6032,4442,292
Total Liabilities & Equity
3,8243,7983,4003,3473,0182,775

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
148.75146.65114.04223.48105.2920.02
Net Cash (Debt)
1,5241,4671,3101,3001,2421,485
Net Cash Growth
7.91%11.99%0.78%4.63%-16.33%-6.35%
Net Cash Per Share
8.798.427.487.347.038.43
Filing Date Shares Outstanding
175.4174.35174.08174.93176.53176.53
Total Common Shares Outstanding
175.4174.35174.08176.49176.53176.53
Working Capital
1,4961,5131,3321,2221,1801,347
Book Value Per Share
16.7216.8215.5014.7513.8512.98
Tangible Book Value
2,6962,7032,6622,5692,4102,258
Tangible Book Value Per Share
15.3715.5015.2914.5613.6512.79
Buildings
-857.74775.81724.27487.54152.45
Machinery
-789.48678.03661.8673.35279.81
Construction In Progress
-53.74189.56186.26231.12637.88